Ptc Therapeutics (PTCT) Asset Writedowns and Impairment (2023 - 2025)

Ptc Therapeutics' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $518000.0 for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment fell 99.67% year-over-year to $518000.0; the TTM figure through Dec 2025 stood at $159.1 million (changed 0.3% YoY), while the FY2025 annual figure was $1.0 million, down 99.36% from the prior year.
• Asset Writedowns and Impairment was $518000.0 for Q4 2025 at Ptc Therapeutics, up from $400000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $217.8 million in Q2 2023 to a low of $100000.0 in Q2 2025.
• Historically, Asset Writedowns and Impairment has averaged $54.1 million across 3 years, with a median of $518000.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment sank 99.91% in 2024, then sank 50.0% in 2025.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $217.8 million in 2023, then retreated by 27.43% to $158.1 million in 2024, then plunged by 99.67% to $518000.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $518000.0 (Q4 2025), $400000.0 (Q3 2025), and $100000.0 (Q2 2025), per Business Quant data.